RU2003105882A - Упорядоченный железосодержащий белок-2 в качестве диагностического средства при нейродегенеративных заболеваниях - Google Patents

Упорядоченный железосодержащий белок-2 в качестве диагностического средства при нейродегенеративных заболеваниях Download PDF

Info

Publication number
RU2003105882A
RU2003105882A RU2003105882/13A RU2003105882A RU2003105882A RU 2003105882 A RU2003105882 A RU 2003105882A RU 2003105882/13 A RU2003105882/13 A RU 2003105882/13A RU 2003105882 A RU2003105882 A RU 2003105882A RU 2003105882 A RU2003105882 A RU 2003105882A
Authority
RU
Russia
Prior art keywords
protein
probe
antibody
mutant
purified
Prior art date
Application number
RU2003105882/13A
Other languages
English (en)
Russian (ru)
Inventor
Вулфф М. КИРШ (US)
Вулфф М. КИРШ
Энтон ЛЕННАРТ (US)
Энтон ЛЕННАРТ
Вэйн Дж. КЕЛЛН (US)
Вэйн Дж. КЕЛЛН
Да-Кинг КЭНГ (US)
Да-Кинг КЭНГ
Родни Л. ЛЕВИН (US)
Родни Л. ЛЕВИН
Трэйси А. РОЯЛТ (US)
Трэйси А. РОЯЛТ
Original Assignee
Лома Линда Юниверсити Медикал Сентер (Us)
Лома Линда Юниверсити Медикал Сентер
ЗЕ ГАВЕНМЕНТ ОФ ЗЕ ЮНАЙТЕД СТЭЙТС ОФ АМЕРИКА, представл емый ЗЕ СЕКРЕТАРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВИСЕЗ (US)
ЗЕ ГАВЕНМЕНТ ОФ ЗЕ ЮНАЙТЕД СТЭЙТС ОФ АМЕРИКА, представляемый ЗЕ СЕКРЕТАРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВИСЕЗ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лома Линда Юниверсити Медикал Сентер (Us), Лома Линда Юниверсити Медикал Сентер, ЗЕ ГАВЕНМЕНТ ОФ ЗЕ ЮНАЙТЕД СТЭЙТС ОФ АМЕРИКА, представл емый ЗЕ СЕКРЕТАРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВИСЕЗ (US), ЗЕ ГАВЕНМЕНТ ОФ ЗЕ ЮНАЙТЕД СТЭЙТС ОФ АМЕРИКА, представляемый ЗЕ СЕКРЕТАРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВИСЕЗ filed Critical Лома Линда Юниверсити Медикал Сентер (Us)
Publication of RU2003105882A publication Critical patent/RU2003105882A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2003105882/13A 2000-08-04 2001-08-06 Упорядоченный железосодержащий белок-2 в качестве диагностического средства при нейродегенеративных заболеваниях RU2003105882A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22286300P 2000-08-04 2000-08-04
US60/222,863 2000-08-04

Publications (1)

Publication Number Publication Date
RU2003105882A true RU2003105882A (ru) 2005-01-20

Family

ID=22834032

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003105882/13A RU2003105882A (ru) 2000-08-04 2001-08-06 Упорядоченный железосодержащий белок-2 в качестве диагностического средства при нейродегенеративных заболеваниях

Country Status (9)

Country Link
US (4) US20020165349A1 (cg-RX-API-DMAC7.html)
EP (1) EP1355933A2 (cg-RX-API-DMAC7.html)
JP (1) JP2004506420A (cg-RX-API-DMAC7.html)
CN (1) CN100535004C (cg-RX-API-DMAC7.html)
AU (1) AU2001284742A1 (cg-RX-API-DMAC7.html)
CA (1) CA2417310A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03000937A (cg-RX-API-DMAC7.html)
RU (1) RU2003105882A (cg-RX-API-DMAC7.html)
WO (1) WO2002012284A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
ATE404877T1 (de) * 2002-08-27 2008-08-15 Kennedy Krieger Inst Magnetische rezonanzbildgebung des mikrovaskulären blutvolumens
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US7838524B2 (en) * 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
JP4653542B2 (ja) * 2005-04-06 2011-03-16 株式会社東芝 画像処理装置
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
CN102308214B (zh) * 2008-12-12 2014-06-25 贝克曼考尔特公司 包含未偶联的藻胆蛋白的多色流式细胞术组合物
US8580230B2 (en) * 2009-02-23 2013-11-12 Kent State University Materials and methods for MRI contrast agents and drug delivery
EP2253716A1 (en) * 2009-05-15 2010-11-24 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Diagnostic methods for the prognosis of a brain tumor
EP2642289A1 (en) 2012-03-20 2013-09-25 Sensirion AG Portable electronic device
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
CA2981533A1 (en) * 2015-04-02 2016-10-06 Crc For Mental Health Ltd Method for predicting risk of cognitive deterioration
WO2018148788A1 (en) * 2017-02-17 2018-08-23 Crc For Mental Health Ltd Method for predicting risk and rate of amyloid deposition and plaque formation
IT201700105483A1 (it) * 2017-09-21 2019-03-21 Braindtech S R L Metodo per la diagnosi e la prognosi di patologie neurodegenerative e neuroinfiammatorie
JP6737995B2 (ja) * 2018-11-29 2020-08-12 株式会社Resvo 精神疾患発症危険状態の診断用バイオマーカー
CN114446392B (zh) * 2022-01-21 2024-01-30 华东理工大学 确认蛋白质与核酸适配体结合时的关键精氨基酸残基位点的方法
CN114457067B (zh) * 2022-02-10 2024-10-25 中国科学院天津工业生物技术研究所 一种低成本快速去除dna合成中错误的方法
CN117417999B (zh) * 2023-11-27 2025-07-25 河南省人民医院 一种与ireb2基因相关的snp分子标记及其应用

Also Published As

Publication number Publication date
MXPA03000937A (es) 2004-08-02
US20020165349A1 (en) 2002-11-07
US20100041060A1 (en) 2010-02-18
US20050260669A1 (en) 2005-11-24
CN100535004C (zh) 2009-09-02
WO2002012284A2 (en) 2002-02-14
EP1355933A2 (en) 2003-10-29
CA2417310A1 (en) 2002-02-14
US20080020393A1 (en) 2008-01-24
AU2001284742A1 (en) 2002-02-18
CN1556815A (zh) 2004-12-22
JP2004506420A (ja) 2004-03-04
WO2002012284A3 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
CA1341033C (en) Precursor protein of apc polypeptide, dna coding for this, and diagnostic use of the dna and of the protein
JP2004506420A5 (cg-RX-API-DMAC7.html)
JP4885122B2 (ja) 癌、器官傷害、および筋肉リハビリテーション/運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー
AU633312B2 (en) Diagnostic method for alzheimer's disease: examination of non-neural tissue
WO2001075454A2 (en) Diagnosis and treatment of alzheimer's disease
JPWO2010052939A1 (ja) アレルゲンのエピトープ又はその候補の検出方法及びその利用
TWI542695B (zh) 牙周病原菌血漿或血清抗體價檢查套組
EP1690870B1 (en) Marker peptide for alzheimer's disease
JP7718270B2 (ja) 血液試料を検体とするタウタンパク質検出方法
US6387639B1 (en) Ma family polypeptides and anti-Ma antibodies
US12000844B2 (en) Diagnostic drug and diagnostic method for Alzheimer's disease
EP1384079A2 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
JP2004506420A (ja) 神経変性疾患のための診断剤としての鉄調節タンパク質−2(irp−2)
WO2003028543A2 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
CA2501464A1 (en) Lmna gene and its involvement in hutchinson-gilford progeria syndrome (hgps) and arteriosclerosis
WO2001013117A2 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
US20030092614A1 (en) ADPI-41, a novel protein isolated from brain tissue homogenate and uses therefor
RU2340900C2 (ru) Диагностика аутизма
WO2000055628A1 (en) Proteins for diagnosis and treatment of breast cancer
JP2024158581A (ja) 神経核内封入体病の検出抗体及びそれを用いた検出方法
WO1999060122A1 (en) Method for examining central nervous system diseases and method for screening remedies
EP3654038A1 (en) Biomarker for cognitive impairment disorders and detection method for cognitive impairment disorders using said biomarker
CN113846155A (zh) 一种cdh23基因突变体及其检测的试剂盒与应用
JP2005124565A (ja) 新規神経ペプチド及びその利用
JP3616274B2 (ja) 中枢神経系疾患の検査方法および治療薬のスクリーニング方法